The FDA declined to approve one of biotech's most closely watched cancer drugs
The FDA declined to approve Summit Therapeutics' lung-cancer drug, ivonescimab, citing insufficient evidence of improved overall survival. The drug is licensed from Akeso. Summit's stock (SMMT) fell 10%, and Akeso's (9926) shares dropped 22.1%. Ivonescimab is already approved in China and is being tested for other cancers. Summit's stock is down 19.2% this year, while the biotech ETF XBI is up 23.9%.
How this was made
The 30-second read
Why it matters
The FDA denial centers on the absence of statistically significant overall survival benefit, not just a lack of efficacy signal, which can materially change the regulatory and trial strategy for the program.
Market read
A direct FDA regulatory decision for a closely watched oncology asset drives immediate repricing of approval odds and timelines.
What to watch
The article notes ivonescimab is already approved in China and is being tested in multiple cancers, which could partially offset US approval delays.
Background
Summit licensed ivonescimab from Akeso in 2022 and is pursuing FDA approval for metastatic non-small-cell lung cancer based on the Phase 3 HARMONi trial.
Ticker impact
FDA declined to approve Summit Therapeutics' lung-cancer drug, saying it must prove statistically significant overall survival benefit.
Likely further pressure as investors reprice the probability and timing of U.S. approval for ivonescimab.
The FDA explicitly required overall survival statistical significance, rejecting the current Phase 3 evidence basis.
Market effects
Raises scrutiny for PD-1/VEGF combination oncology programs where progression-free survival improves but overall survival is not statistically significant.
US biotech sentiment likely negative; foreign-listed Akeso also fell sharply, suggesting read-across risk for partnered assets.
Highlights FDA’s strict overall-survival bar, which can affect global development strategies and investor expectations for similar trials.
Counterpoint
The FDA’s feedback may still allow a path to approval via additional analyses or new trials, limiting long-term impairment if the company can generate overall-survival evidence.
Key entities
- companySummit Therapeutics
US biotech developing ivonescimab for metastatic non-small-cell lung cancer; FDA declined approval.
- drugivonescimab
PD-1 and VEGF-targeting lung-cancer therapy licensed by Summit from Akeso.
- companyAkeso
Chinese biotech that developed ivonescimab and saw its Hong Kong shares fall.
- regulatorFDA
Required statistically significant overall survival improvement for approval.




